[{"id":"61a3c132-1e83-4fa7-ac20-da8e3c1ecabc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05702853","created_at":"2023-01-27T15:00:01.356Z","updated_at":"2024-07-02T16:35:27.052Z","phase":"Phase 1/2","brief_title":"Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL","source_id_and_acronym":"NCT05702853","lead_sponsor":"Medical University of South Carolina","biomarkers":" BCL2 • CD19 • BCL6","pipe":" | ","alterations":" CD19 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • CD19 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD19-CD34t metabolically programmed CAR transduced T-cells"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 11/06/2023","start_date":" 11/06/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2023-12-05"}]